Antonides and colleagues present fundamental concepts of cost–effectiveness analysis (CEA) and they discuss the interpretation of these analyses.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thoracic
June 13, 2018
This is a video demonstrating the use of the FlexDex™ needle holder to perform a left VATS diaphragm plication.
June 11, 2018
The author discusses how to acquire new skills and techniques as a young surgeon.
June 7, 2018
G. Alexander Patterson of the Washington University School of Medicine in St Louis, Missouri, discusses oncologic outcomes after VATS resections.
June 5, 2018
Timman and colleagues assessed the functional outcomes of patients who underwent laryngotracheal resection (LTR) and reconstruction for benign laryngotracheal stenosis. Between 1996 and 2017, 119 consecutive patients underwent LTR (n = 47) or end-to-end segmented tracheal resection (n = 56).
June 4, 2018
This video demonstrates a carinal resection, which was a challenging operation.
June 4, 2018
Risk-prediction models are well-known in cardiac surgery—the EuroSCORE and STS models being some of the most recognized. They are used for risk stratification, decision-making, and benchmarking. However, development of these models can be complex and once a model is developed, it is important to validate it.
June 1, 2018
Kim and colleagues retrospectively analyzed long-term patency of reimplanted branch vessels following thoracoabdominal aortic aneurysm repair in 168 patients. Patency rates were high for visceral branches. For segmental arteries, patency rates depended on reimplantation technique and were worst for graft interpositions.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
May 30, 2018
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.